RESEARCH TRIANGLE PARK, N.C. (AP) -- Spanish health care company Grifols plans to buy Talecris Biotherapeutics in a cash-and-stock deal valued at about $3.4 billion.
Grifols will offer $19 in cash and a portion of its newly issued, nonvoting shares for each share of the Research Triangle Park, N.C., company. The companies say the deal's implied price of $26.16 represents a 53 percent premium to the average closing price of Talecris shares over the past 30 days.
Talecris develops treatments for immune deficiencies and hemophilia, among other therapeutic areas, and operates a network of plasma collection centers.
Grifols makes plasma derivatives, IV therapy, diagnostic systems and medical materials.